Richard S. Finn, MD
Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses new CDK 4/6 inhibitors for the treatment of breast cancer.
Other CDK inhibitors have been around a lot longer than palbociclib but have not broken out of the pack to show robust activity. Palbociclib, as a first-in-class CDK 4/6 inhibitor, has shown such benefit that there are now other CDK 4/6 inhibitors being developed.
These other drugs are in early phase and a ways behind, Finn says, so it remains to be seen how they can compete with palbociclib in the space.